The announcement that an important clinical program is moving forward has put investors in a good mood.
News & Analysis: Novan, Inc.
Shares collapsed after the company released disappointing results in one of its two phase 3 clinical trials.
The "tentative" status may be making investors jittery.
It had to be someone.
A recently acquired drug fails a late-stage clinical trial.
With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs.
The company is smart with its money, but is relying on one drug for some time.
A new treatment for attention deficit disorder is selling so briskly, it could mean big money.